Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis.
Methysergide (Sansert) is known to cause mitral and aortic valvular fibrosis and dysfunction, but has generally not been known to damage right heart valves or the myocardium, and cardiac fibrosis has not been considered to be a risk if therapy is intermittently interrupted. The woman who is the subject of this case report developed catheterization-proven severe tricuspid and moderate aortic and mitral regurgitation during noncontinuous therapy with methysergide. In addition, right ventricular endomyocardial biopsy revealed extensive endocardial and intramyocardial fibrosis.
D001022:Aortic Valve Insufficiency / Q000139:chemically induced*; D004719:Endomyocardial Fibrosis / Q000139:chemically induced*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008784:Methysergide / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy; D008944:Mitral Valve Insufficiency / Q000139:chemically induced*; D011665:Pulmonary Valve Insufficiency / Q000139:chemically induced
D008784:Methysergide